EPEwa Parfieniuk

Ewa Parfieniuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ewa Parfieniuk has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prenatal circulating microRNA signatures of foetal Down syndrome

    by Monika Zbucka-Kretowska, Magdalena Niemira, Magdalena Paczkowska-Abdulsalam, Agnieszka Bielska, Anna Szalkowska, Ewa Parfieniuk, Michal Ciborowski, Slawomir Wolczynski, Adam Kretowski

    The altered expression pattern of miRNAs might potentially reflect anomalies related to foetal chromosomal aberrations. The aim of the study was to determine the expression level of miRNAs in plasma of pregnant women with foetal Down syndrome (DS). Out of 198 amniocentesis performed at 15–18 weeks of gestation, within a group of 12 patients with foetal DS and 12 patients with uncomplicated pregnancies, who delivered healthy newborns at term, we examined the expression level of 800 miRNAs using the NanoString technology. Our study revealed that there are 6 miRNAs were upregulated (hsa-miR-15a, hsa-let-7d, hsa-miR-142, hsa-miR-23a, hsa-miR-199, hsa-miR-191) and 7 were downregulated (hsa-miR-1290, hsa-miR-1915, hsa-miR30e, hsa-miR-1260, hsa-miR-483, hsa-miR-548, hsa-miR-590) in plasma samples of women with foetal DS syndrome. The genes regulated by identified miRNAs are involved in central nervous system development, congenital abnormalities and heart defects. The results of the present study yielded information on DS-specific miRNA expression signature, which can further help to design a panel of miRNAs as a non-invasive test for DS diagnosis. We believe that identified miRNAs may attend in the pathogenesis of DS and would potentially make a significant role for the future preventive therapies.


  • Metabolic fingerprinting of carp and rainbow trout seminal plasma

    by Mariola A. Dietrich, Paulina Samczuk, Michal Ciborowski, Joanna Nynca, Ewa Parfieniuk, Karolina Pietrowska, Tomasz Kowalczyk, Adam Kretowski, Andrzej Ciereszko


  • Untargeted metabolomics: an overview of its usefulness and future potential in prenatal diagnosis

    by Ewa Parfieniuk, Monika Zbucka-Kretowska, Michal Ciborowski, Adam Kretowski, Coral Barbas

    Introduction: Metabolomics opens up new avenues for biomarker discovery in different branches of medicine, including perinatology. Chromosomal aberration, preterm delivery (PTD), congenital heart defects, spina bifida, chorioamnionitis, and low birth weight are the main perinatal pathologies. Investigations using untargeted metabolomics have found the candidate metabolites for diagnostic biomarkers. Areas covered: This review describes areas of prenatal diagnosis in which untargeted metabolomics has been used. Data on the disease, type of sample, techniques used, number of samples used in the study, and metabolites obtained including the sign of their regulation are summarized. Expert commentary: Untargeted metabolomics is a powerful tool which can shed a new light on prenatal diagnostics. It helps to discover affected metabolic pathways what may help to reveal disease pathogenesis and propose potential biomarkers. Among others, glycerol and 2- and 3-hydroxybutyrate were proposed as markers of chromosomal aberration. Serum metabolic signature of PTD was characterized by increased lipids and decreased levels of hypoxanthine, tryptophane, and pyroglutamic acid. Lower level lipids and vitamin D3 metabolites together with increased bilirubin level in maternal serum were associated with macrosomia. However, to give a real value to those assays and allow their clinical application multicenter, large cohort validation studies are necessary.


  • Maternal plasma metabolic fingerprint indicative for fetal Down syndrome

    by Ewa Parfieniuk, Paulina Samczuk, Tomasz Kowalczyk, Karolina Pietrowska, Magdalena Niemira, Magdalena Paczkowska‐Abdulsalam, Slawomir Wolczynski, Adam Kretowski, Michal Ciborowski, Monika Zbucka‐Kretowska

    Objective The objective of the study was to perform maternal plasma metabolic fingerprinting to evaluate differences in plasma metabolites between healthy and Down syndrome (DS) pregnancies and to indicate novel non‐invasive markers for DS prenatal diagnostics. Methods This was a case‐control study of pregnancies between 15th‐ 18th gestational week. LC‐MS‐based metabolic fingerprinting of plasma samples was performed. Results Levels of five metabolites were significantly lower in the plasma of DS pregnancies. The majority of the statistically significant metabolites may be connected with fetal brain and central nervous system development (e.g. fatty acid amides). According to the receiver operating characteristic (ROC), the combination of linoleamide and piperine has the highest diagnostic potential: AUC=0.878, sensitivity 100% and specificity 73.3%. Conclusions The study indicates disturbances in maternal metabolic pathways evoked by fetal DS. Novel potential maternal plasma metabolomic markers for non‐invasive prenatal diagnostics of fetal DS are proposed.


  • Evaluation of Bisphenol A influence on endocannabinoid system in pregnant women

    by Monika Zbucka-Kretowska, Robert Zbucki, Ewa Parfieniuk, Maciej Maslyk, Urszula Lazarek, Wojciech Miltyk, Jan Czerniecki, Slawomir Wolczynski, Adam Kretowski, Michal Ciborowski


  • An exploratory LC‐MS‐based metabolomics study reveals differences in aqueous humor composition between diabetic and non‐diabetic patients with cataract

    by Karolina Pietrowska, Diana Anna Dmuchowska, Pawel Krasnicki, Aleksandra Bujalska, Paulina Samczuk, Ewa Parfieniuk, Tomasz Kowalczyk, Malgorzata Wojnar, Zofia Mariak, Adam Kretowski, et al.

    Cataract is the leading cause of blindness worldwide. Epidemiological studies revealed up to a fivefold increased prevalence of cataracts in diabetic subjects. Metabolomics is nowadays frequently implemented to understand pathophysiological processes responsible for disease occurrence and progression. It has also been used recently to study the metabolic composition of aqueous humor (AH). AH is a transparent fluid which fills the anterior and posterior chambers of the eye. It supplies nutrients and removes metabolic waste from avascular tissues in the eye. The aim of this study was to use metabolomics to compare the AH of diabetic and non‐diabetic patients undergoing cataract surgery. Several antioxidants (methyltetrahydrofolic acid, taurine, niacinamide, xanthine, and uric acid) were found decreased (−22 to −61%,p‐value 0.05–0.003) in AH of diabetics. Also amino acids (AA) and derivatives were found decreased (−21 to −36%,p‐value 0.05–0.01) while glycosylated AA increased (+75–98%,p‐value 0.03–0.009) in this group of patients. Metformin was detected in AH of people taking this drug. To our knowledge, this is the first metabolomics study aiming to assess differences in AH composition between diabetic and non‐diabetic patients with cataract. An increased oxidative stress and perturbations in amino acid metabolism in AH may be responsible for earlier cataract onset in diabetic patients.


  • Serum Metabolic Fingerprinting Identified Putatively Annotated Sphinganine Isomer as a Biomarker of Wolfram Syndrome

    by Agnieszka Zmyslowska, Michal Ciborowski, Maciej Borowiec, Wojciech Fendler, Karolina Pietrowska, Ewa Parfieniuk, Karolina Antosik, Aleksandra Pyziak, Arleta Waszczykowska, Adam Kretowski, et al.

    Wolfram syndrome (WFS) is an example of a rare neurodegenerative disease with coexisting endocrine symptoms including diabetes mellitus as the first clinical symptom. Treatment of WFS is still only symptomatic and associated with poor prognosis. Potential markers of disease progression that could be useful for possible intervention trials are not available. Metabolomics has potential to identify such markers. In the present study, serum fingerprinting by LC-QTOF-MS was performed in patients with WFS (n = 13) and in patients with T1D (n = 27). On the basis of the obtained results, aminoheptadecanediol (17:0 sphinganine isomer) (+50%, p = 0.02), as the most discriminatory metabolite, was selected for validation. The 17:0 sphinganine isomer level was determined using the LC-QQQ method in the samples from WFS patients at two time points and compared with samples obtained from patients with T1D (n = 24) and healthy controls (n = 24). Validation analysis showed higher 17:0 sphinganine isomer level in patients with WFS compared to patients with T1D (p = 0.0097) and control group (p < 0.0001) with progressive reduction of its level after two-year follow-up period. Patients with WFS show a unique serum metabolic fingerprint, differentiating them from patients with T1D. Sphinganine derivate seems to be a marker of the ongoing process of neurodegeneration in WFS patients.


  • Development of LC‐QTOF‐MS method for human lung tissue fingerprinting. A preliminary application to nonsmall cell lung cancer

    by Michal Ciborowski, Joanna Kisluk, Karolina Pietrowska, Paulina Samczuk, Ewa Parfieniuk, Tomasz Kowalczyk, Miroslaw Kozlowski, Adam Kretowski, Jacek Niklinski

    The major histologic subtypes of non‐small cell lung cancer (NSCLC) include adenocarcinoma (ADC), squamous cell lung carcinoma (SCC), and large‐cell carcinoma (LCC). Clinical trials of targeted agents and newer chemotherapy agents yielded differences in outcomes according to histologic subgroups providing a rationale for histology‐based treatment in NSCLC. Currently, NSCLC subtyping is performed based on histopathological examinations and immunohistochemistry. However available methods leave about 10% of NSCLC cases as not otherwise specified. The purpose of this study was development of an LC‐QTOF‐MS method for human lung tissue metabolic fingerprinting that could discriminate NSCLC histological subtypes and propose biomarkers candidates that could support proper NSCLC diagnosis. Metabolites were extracted with acetonitrile or methanol/ethanol and different chromatographic conditions were tested. In the final method 10 mg of lung tissue was homogenized with 50% methanol and metabolites were extracted with acetonitrile. Metabolites were separated on C8‐RP and HILIC columns. About 3500 and 2000 of metabolic features (in both ion modes) were detected with good repeatability (CV < 20%) by RP and HILIC methods, respectively. Lung tumor and control tissue samples obtained from NSCLC patients were analyzed with developed methodology. Acylcarnitines, fatty acids, phospholipids, and amino acids were found more abundant in tumor as compared to control tissue. Acylcarnitines, lysophospholipids, creatinine, creatine, and alanine were identified as potential targets enabling classification of NSCLC subtypes.